NEW YORK, June 13, 2018 /PRNewswire/ -- Depression Drugs Market - Overview
This report analyzes the global depression drugs market in terms of its current and future scenario. Increase in prevalence of major depression disorders, rise in government initiatives in creating awareness about depression drugs, and growth in geriatric population across the world are expected to drive the depression drugs market during the forecast period.
Read the full report: https://www.reportlinker.com/p05439363
The report on the global depression drugs market comprises an elaborate executive summary, including a market snapshot that provides information on various segments.It also provides information and data analysis of the global market with respect to its segments based on drug class, disease type, distribution channel, and geography.
A detailed qualitative analysis of drivers and restraints, opportunities, and trends has been provided in the market overview section.Additionally, the section comprises product pipeline analysis to help understand the scope of the market.
The section also provides market share analysis in terms of segments, geography and key players, thus presenting a thorough analysis of the overall competitive scenario in the global depression drugs market.
The global depression drugs market has been classified on the basis of drug class, disease type, distribution channel, and region.Based on drug class, the market has been categorized into atypical antipsychotics, serotonin?norepinephrine reuptake inhibitor, selective serotonin reuptake inhibitor, central nervous system (CNS) stimulant, and others.
In terms of disease type, the market has been classified into major depressive disorder, schizophrenia and bipolar I disorder, selective serotonin reuptake inhibitor induced, and others. Based on distribution channel, the market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Geographically, the global depression drugs market has been categorized into five major regions and key countries in those regions: North America (U.S. and Canada), Europe (Germany, France, Italy, Spain, U.K., and Rest of Europe), Asia Pacific (China, Japan, India, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, Israel, GCC, and Rest of Middle East & Africa).
The report also profiles major players operating in the global depression drugs market based on various attributes, such as, company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Pfizer Inc., AstraZeneca, Allergan USA, Inc., Novartis AG, GlaxoSmithKline, and Takeda Pharmaceutical Company Ltd.
The global depression drugs market has been segmented as below:
Global Depression Drugs Market, by Drug Class
Atypical antipsychotics
Serotonin-norepinephrine reuptake inhibitors
Selective serotonin reuptake inhibitors
CNS stimulants
Others (Benzodiazepines and miscellaneous antidepressants)
Global Depression Drugs Market, by Disease Type
Major depressive disorders
Schizophrenia and bipolar I disorder (manic depression)
SSRI induced
Others (attention deficit hyperactivity disorder and anxiety disorders)
Global Depression Drugs Market, by Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
Global Depression Drugs Market, by Geography
North America
U.S.
Canada
Europe
Germany
France
Italy
Spain
U.K.
Rest of Europe
Asia Pacific
China
Japan
India
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Israel
Rest of Middle East & Africa
Read the full report: https://www.reportlinker.com/p05439363
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
These press releases may also interest you
|